[EN] CYCLOALKENYL ARYL DERIVATIVES FOR CETP INHIBITOR [FR] DÉRIVÉS CYCLOALCÉNYL ARYLE POUR UN INHIBITEUR DE LA PROTÉINE DE TRANSFERT DU CHOLESTÉROL ESTÉRIFIÉ (CETP)
Zur Synthese von Tiliacora-Alkaloiden, 2. Mitt.: Darstellung des unsymmetrischen Biphenyl-Schwanzteils
摘要:
Die Biphenyl-Derivate S-1 和 S-3 werden aus den Phenylessigsäureestern 3, 4 和 5 durch gemischte Ullmann-Reaktion erhalten。Aufgrund der selektiv abspaltbaren Carboxy-Schutzgruppen eignen sich S-1 和 S-3 zur konstitutionsselektiven Verknüpfung mit dem früher beschriebenen unsymmetrischen Dibenzo-1,4-dioxin-Derivat K1)。
The present invention relates to cycloalkenyl aryl derivatives, isomers thereof, pharmaceutically acceptable salts thereof, hydrates thereof, or solvates thereof; a method for preparing the derivatives; and pharmaceutical compositions containing the same. The compounds of the present invention show the effect of CETP activity inhibition. It means that the compounds can increase HDL-cholesterol and decrease LDL-cholesterol.
[EN] CYCLIC AMINE SUBSTITUTED OXAZOLIDINONE CETP INHIBITOR<br/>[FR] INHIBITEUR DE CETP SUBSTITUÉ PAR DES AMINES CYCLIQUES À BASE D'OXAZOLIDINONE
申请人:MERCK SHARP & DOHME
公开号:WO2012058187A1
公开(公告)日:2012-05-03
CCompounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compound of Formula I, A3 is a substitiuted phenyl group or indanyl group.Formula (I).
Zur synthese von Tiliacora-Alkaloiden — III: Synthese von Biarylen durch Ullmann-Kupplung
作者:Gregor Radau、Ralf Büllesbach、Peter Pachaly
DOI:10.1016/0040-4020(96)00937-4
日期:1996.11
Unter Anwendung schonender Reaktionsbedingungen können verschieden substituierte Biaryle (2, 13, 16, 19) als Hauptprodukte mit guten Ausbeuten synthetisiert werden.
Compounds having the structure of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula (I), B is a cyclic group other than phenyl, and B has a cyclic substituent at a position that is ortho to the position at which B is connected to the remainder of the structure of Formula (I). The 5-membered ring of Formula (I) has a second cyclic substituent in addition to B.
Compounds having the structure of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula (I), B is a cyclic group other than phenyl, and B has a cyclic substituent at a position that is ortho to the position at which B is connected to the remainder of the structure of Formula (I). The 5-membered ring of Formula (I) has a second cyclic substituent in addition to B.